Elisabeth de Darkó
Profile
Elisabeth de Darkó served as the Chief Executive Officer of Valderm ApS from 2006 to 2014.
She also worked as the Director of Medical & Regulatory Affairs at Yamanouchi Nordic.
Former positions of Elisabeth de Darkó
| Companies | Position | End |
|---|---|---|
| Yamanouchi Nordic | Chief Tech/Sci/R&D Officer | - |
Valderm ApS
 Valderm ApS Pharmaceuticals: MajorHealth Technology Valderm ApS is focused on the development of the second generation anthracycline valrubicin for innovative once daily topical treatment of hyper proliferative skin diseases e.g. psoriasis. Preclinical studies have confirmed the anti-proliferative effect of valrubicin and an attractive safety profile upon repeated topical applications has been documented. The company was founded in 2003 and is headquartered in Lyngby, Denmark. | Chief Executive Officer | - |
Experiences
Positions held
Linked companies
| Private companies | 2 |
|---|---|
Valderm ApS
Valderm ApS Pharmaceuticals: MajorHealth Technology Valderm ApS is focused on the development of the second generation anthracycline valrubicin for innovative once daily topical treatment of hyper proliferative skin diseases e.g. psoriasis. Preclinical studies have confirmed the anti-proliferative effect of valrubicin and an attractive safety profile upon repeated topical applications has been documented. The company was founded in 2003 and is headquartered in Lyngby, Denmark. | Health Technology |
| Yamanouchi Nordic |
- Stock Market
- Insiders
- Elisabeth de Darkó
